Show simple item record

dc.contributor.authorGalli, Francesco
dc.contributor.authorMouly, Vincent
dc.contributor.authorButler-Browne, Gillian
dc.contributor.authorCossu, Giulio; email: giulio.cossu@manchester.ac.uk
dc.date.accessioned2021-11-19T01:37:54Z
dc.date.available2021-11-19T01:37:54Z
dc.date.issued2021-11-01
dc.date.submitted2021-07-06
dc.identifierpubmed: 34736920
dc.identifierpii: S0014-4827(21)00464-X
dc.identifierdoi: 10.1016/j.yexcr.2021.112908
dc.identifier.citationExperimental cell research, volume 409, issue 1, page 112908
dc.identifier.urihttp://hdl.handle.net/10034/626378
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: received 2021-07-06, revised 2021-09-21, accepted 2021-10-29
dc.descriptionPublication status: aheadofprint
dc.description.abstractFor decades now, cell transplantation has been considered a possible therapeutic strategy for muscular dystrophy, but failures have largely outnumbered success or at least encouraging outcomes. In this review we will briefly recall the history of cell transplantation, discuss the peculiar features of skeletal muscle, and dystrophic skeletal muscle in particular, that make the procedure complicated and inefficient. As there are many recent and exhaustive reviews on the various myogenic cell types that have been or will be transplanted, we will only briefly describe them and refer the reader to these reviews. Finally, we will discuss possible strategies to overcome the hurdles that prevent biological efficacy and hence clinical success. [Abstract copyright: Copyright © 2021. Published by Elsevier Inc.]
dc.languageeng
dc.sourceeissn: 1090-2422
dc.subjectClinical trials
dc.subjectMyogenic progenitor cells
dc.subjectCell transplantation
dc.subjectMuscular dystrophies
dc.titleChallenges in cell transplantation for muscular dystrophy.
dc.typearticle
dc.date.updated2021-11-19T01:37:54Z
dc.date.accepted2021-10-29


This item appears in the following Collection(s)

Show simple item record